165 related articles for article (PubMed ID: 10663614)
1. New therapeutic approaches in primary systemic AL amyloidosis.
Sezer O; Eucker J; Schmid P; Possinger K
Ann Hematol; 2000 Jan; 79(1):1-6. PubMed ID: 10663614
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment of AL amyloidosis.
Sezer O; Eucker J; Jakob C; Possinger K
Clin Nephrol; 2000 Jun; 53(6):417-23. PubMed ID: 10879660
[TBL] [Abstract][Full Text] [Related]
3. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
[TBL] [Abstract][Full Text] [Related]
4. Novel approaches to the treatment of primary amyloidosis.
Sezer O; Niemöller K; Jakob C; Langelotz C; Eucker J; Possinger K
Expert Opin Investig Drugs; 2000 Oct; 9(10):2343-50. PubMed ID: 11060811
[TBL] [Abstract][Full Text] [Related]
5. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
6. [Current treatment of AL amyloidosis].
Kovacsovics T
Rev Med Suisse Romande; 2000 Oct; 120(10):771-5. PubMed ID: 11109905
[TBL] [Abstract][Full Text] [Related]
7. Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
Tazawa K; Katoh N; Shimojima Y; Matsuda M; Ikeda S
Amyloid; 2009 Dec; 16(4):243-5. PubMed ID: 19922338
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
[TBL] [Abstract][Full Text] [Related]
9. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
11. High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement.
Shimojima Y; Matsuda M; Ishii W; Koyama J; Yamamoto K; Shimodaira S; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):484-9. PubMed ID: 15942100
[TBL] [Abstract][Full Text] [Related]
12. Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis.
Schonland SO; Perz JB; Hundemer M; Hegenbart U; Kristen AV; Hund E; Dengler TJ; Beimler J; Zeier M; Singer R; Linke RP; Ho AD; Goldschmidt H
Transplantation; 2005 Sep; 80(1 Suppl):S160-3. PubMed ID: 16286897
[TBL] [Abstract][Full Text] [Related]
13. [Therapy options in systemic AL-amyloidosis with renal involvement].
Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
[TBL] [Abstract][Full Text] [Related]
14. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.
Sanchorawala V
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1131-44. PubMed ID: 25459183
[TBL] [Abstract][Full Text] [Related]
15. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
Comenzo RL; Vosburgh E; Simms RW; Bergethon P; Sarnacki D; Finn K; Dubrey S; Faller DV; Wright DG; Falk RH; Skinner M
Blood; 1996 Oct; 88(7):2801-6. PubMed ID: 8839879
[TBL] [Abstract][Full Text] [Related]
16. No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement.
Zeier M; Perz J; Linke RP; Donini U; Waldherr R; Andrassy K; Ho AD; Goldschmidt H
Nephrol Dial Transplant; 2003 Dec; 18(12):2644-7. PubMed ID: 14605290
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of amyloidosis].
Wien TN
Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1397-400. PubMed ID: 18552901
[TBL] [Abstract][Full Text] [Related]
18. Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
Tazawa K; Katoh N; Shimojima Y; Matsuda M; Ikeda S
Amyloid; 2009; 16(3):183-5. PubMed ID: 19590992
[TBL] [Abstract][Full Text] [Related]
19. Primary systemic amyloidosis.
Comenzo RL
Curr Treat Options Oncol; 2000 Apr; 1(1):83-9. PubMed ID: 12057064
[TBL] [Abstract][Full Text] [Related]
20. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]